Wuxi Biologics (Cayman) Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zhi Sheng Chen
- Full Time Employees
- 13,252
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 108, Meiliang Road Wuxi JS China 214092
- IPO Date
- Jun 13, 2017
- Website
- wuxibiologics.com
- Similar Companies
- Business
- WuXi Biologics (Cayman) Inc. WuXi Biologics (Cayman) Inc. (2269.HK) is a leading global contract research, development and manufacturing organization (CRDMO) that provides comprehensive end-to-end biologics solutions, including biologics discovery, cell line development, process and product development, analytical testing, clinical and commercial cGMP manufacturing of drug substances and drug products, as well as advanced modalities such as antibody-drug conjugates via its subsidiary WuXi XDC; the company leverages proprietary technology platforms like WuXia cell line development (including the recently launched WuXia 4.0 with TrueSite TI targeted integration platform in September 2025 for accelerated high-titer biologics and WuXiHigh 2.0 in June 2025 for high-concentration formulations up to 230 mg/mL), WuXiBody for multispecific antibodies, and others for bispecific T-cell engagers, fusion proteins, and Fab fragments. Founded in 2010 and headquartered in Wuxi, China, WuXi Biologics operates extensive manufacturing facilities across China (Wuxi, Suzhou, Hangzhou), the United States, Ireland (Dundalk), Germany (Wuppertal), and Singapore, serving top global pharmaceutical and biotech companies with a focus on complex biologics for oncology, autoimmune, and inflammatory diseases. Recent developments include a January 2025 partnership with Candid Therapeutics granting exclusive global rights to preclinical tri-specific T-cell engager antibodies from its WuXiBody platform (up to $925 million in milestones plus royalties), solid 2025 interim results with 24.9% YoY commercial manufacturing revenue growth, addition of 86 new integrated projects bringing the total to 864 (including record pre-clinical and early-phase pipelines), expansion of global capacity to mitigate supply chain risks, and GMP release of the new DP3 drug product facility at its Wuxi site in August 2025.
Company News
WuXi Biologics (Cayman) (OTCMKTS:WXXWY) Hits New 1-Year High – Still a Buy?
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Down 81.8% in July
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
WuXi Biologics Reports Record 2025 Annual Results
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target